Overview
Neonatal myasthenia gravis (NMG) is a rare autoimmune disorder characterized by transient muscle weakness and fatigability in newborns, typically due to transplacental transfer of maternal antibodies against the acetylcholine receptor (AChR) or other neuromuscular junction components. This condition primarily affects infants born to mothers with myasthenia gravis (MG), impacting neuromuscular function and potentially leading to significant respiratory distress and feeding difficulties. Given the vulnerability of neonates and the potential for severe complications, early recognition and management are critical in day-to-day practice to ensure optimal outcomes 1.Pathophysiology
NMG arises from the transplacental passage of maternal autoantibodies, predominantly directed against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), which target and disrupt the neuromuscular junction in the neonate. These antibodies interfere with the normal function of acetylcholine receptors, leading to impaired neuromuscular transmission and subsequent muscle weakness. The severity of NMG can vary widely, influenced by factors such as the maternal disease severity, antibody titers, and the specific autoantibodies involved. While the neonatal immune system is typically immature and less likely to produce antibodies against self-antigens, the presence of maternal antibodies can temporarily disrupt neuromuscular function until these antibodies are cleared from the infant's system, usually within weeks to months 1.Epidemiology
NMG is exceedingly rare, with an incidence estimated to be around 1 in 10,000 to 1 in 15,000 live births, contingent on maternal MG status 1. The condition predominantly affects infants born to mothers with generalized myasthenia gravis, particularly those with high titers of AChR antibodies. There is no significant geographic or ethnic predilection noted in the literature, though the overall prevalence of MG varies across different populations. Trends over time suggest that with improved maternal MG management, the incidence of NMG may be decreasing, though robust longitudinal data are limited 1.Clinical Presentation
Neonatal myasthenia gravis typically manifests within the first few days to weeks after birth, presenting with symptoms such as feeding difficulties, respiratory distress, hypotonia, and generalized muscle weakness. Common clinical features include:
Feeding difficulties: Poor suck, choking, or aspiration.
Respiratory symptoms: Apnea, tachypnea, or cyanosis.
Muscle weakness: Facial muscle weakness leading to ptosis, poor head control, and generalized hypotonia.
Red-flag features: Severe respiratory failure requiring mechanical ventilation, prolonged neonatal intensive care unit (NICU) stays, and in rare cases, mortality.Prompt recognition of these symptoms is crucial for timely intervention 1.
Diagnosis
The diagnosis of NMG involves a combination of clinical suspicion based on maternal history and specific diagnostic tests:
Clinical history: Maternal diagnosis of myasthenia gravis, particularly with generalized disease and high AChR antibody titers.
Physical examination: Assessment of muscle weakness, particularly in facial muscles, sucking reflex, and respiratory effort.
Electrophysiological studies: Repetitive nerve stimulation (RNS) of motor nerves can show decremental response in affected muscles.
Serological testing: Measurement of maternal and neonatal AChR antibodies; neonatal titers may be lower but still indicative.
Differential diagnosis:
- Congenital myopathies: Muscle biopsy may differentiate.
- Infantile spinal muscular atrophy: Genetic testing and clinical progression patterns help distinguish.
- Hypoxic-ischemic encephalopathy: Neuroimaging and clinical context are key differentiators.Specific criteria and tests:
Clinical criteria: Neonatal symptoms temporally related to birth, maternal MG history.
Electrophysiological tests: Repetitive nerve stimulation showing decremental response (amplitude reduction >10% with repetitive stimulation).
Serological tests: AChR antibody levels in mother ≥ 0.3 nmol/L and neonatal levels detectable (though often lower than maternal levels).Management
Initial Management
Supportive care: Close monitoring in a neonatal intensive care unit (NICU) for respiratory support, including mechanical ventilation if necessary.
Nutritional support: Nasogastric feeding or parenteral nutrition if oral feeding is inadequate.Pharmacological Treatment
First-line:
- Immunoglobulin therapy: Intravenous immunoglobulin (IVIG) at a dose of 1-2 g/kg over 2-5 days can provide rapid improvement by temporarily neutralizing maternal antibodies.
- Plasmapheresis: Considered in severe cases, aiming to reduce maternal antibody levels rapidly.
Second-line:
- Cholinesterase inhibitors: Pyridostigmine may be used cautiously, starting at low doses (e.g., 2.5 mg/kg/day in divided doses) and titrating based on response and side effects.
- Corticosteroids: Prednisolone may be considered in refractory cases, starting at low doses (e.g., 1-2 mg/kg/day) and gradually tapering.Monitoring:
Regular assessment of respiratory status, feeding ability, and muscle strength.
Serial AChR antibody levels in neonates to monitor clearance of maternal antibodies.Refractory Cases
Specialist referral: Consultation with pediatric neurologists and immunologists for advanced management options.
Immunosuppressive therapy: Azathioprine or mycophenolate mofetil may be considered in severe, refractory cases, under close supervision.Contraindications:
Avoid high-dose corticosteroids in neonates due to potential side effects unless absolutely necessary.Complications
Acute complications: Severe respiratory failure requiring mechanical ventilation, aspiration pneumonia.
Long-term complications: Rare but include developmental delays if prolonged neonatal illness affects overall health.
Management triggers: Persistent respiratory distress, feeding intolerance, or lack of clinical improvement within the expected timeframe (typically weeks) should prompt escalation of care.Prognosis & Follow-up
The prognosis for NMG is generally favorable, with most infants showing significant improvement within weeks to months as maternal antibodies are cleared. Key prognostic indicators include:
Initial severity: Severe respiratory involvement at presentation may correlate with longer recovery periods.
Maternal antibody levels: Higher initial titers may predict a longer duration of symptoms.Recommended follow-up:
Short-term: Weekly to biweekly assessments in NICU until clinical stability achieved.
Long-term: Regular pediatric follow-ups at 1-3 months, 6 months, and annually to monitor developmental milestones and ensure no residual neuromuscular issues.Special Populations
Pregnancy
Maternal MG management: Close monitoring and individualized treatment adjustments are crucial to minimize risk of NMG. Thymectomy and optimal immunosuppressive therapy can influence outcomes positively 1.
Neonatal surveillance: High vigilance for NMG symptoms in infants born to mothers with active MG, especially those with high antibody titers.Pediatrics
Clinical presentation: Similar to NMG but can overlap with congenital myasthenic syndromes; genetic testing may be necessary for differential diagnosis 23.
Treatment approach: Tailored to the severity and specific underlying pathology, often requiring multidisciplinary care.Key Recommendations
Early recognition and NICU admission for neonates born to mothers with myasthenia gravis, especially with high AChR antibody titers. (Evidence: Strong 1)
Initiate supportive care including respiratory support and nutritional assistance promptly. (Evidence: Strong 1)
Administer IVIG at 1-2 g/kg over 2-5 days for rapid improvement in severe cases. (Evidence: Moderate 1)
Consider plasmapheresis in neonates with severe, refractory symptoms to rapidly reduce maternal antibody levels. (Evidence: Moderate 1)
Monitor AChR antibody levels in neonates to assess clearance of maternal antibodies over time. (Evidence: Moderate 1)
Use pyridostigmine cautiously as a second-line therapy, starting at low doses and titrating based on response. (Evidence: Moderate 1)
Refer to specialists for refractory cases involving advanced immunosuppressive therapy. (Evidence: Expert opinion)
Regular follow-up for developmental monitoring in infants who experienced severe neonatal myasthenia gravis. (Evidence: Moderate 1)
Optimize maternal MG management prenatally to reduce risk of severe neonatal complications. (Evidence: Moderate 1)
Genetic testing should be considered in pediatric cases to rule out congenital myasthenic syndromes. (Evidence: Moderate 23)References
1 Su M, Liu X, Wang L, Song J, Zhou Z, Luo S et al.. Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis. Orphanet journal of rare diseases 2022. link
2 Melbourne Chambers R, Forrester S, Gray R, Tapper J, Trotman H. Myasthenia gravis in Jamaican children: a 12-year institutional review. Paediatrics and international child health 2012. link
3 Morita MP, Gabbai AA, Oliveira AS, Penn AS. Myasthenia gravis in children: analysis of 18 patients. Arquivos de neuro-psiquiatria 2001. link
4 Bjerre I, Hallberg A. Myasthenia gravis. Immunological studies in a young child treated with thymectomy and immunosuppressive drugs. Neuropediatrics 1983. link